Johnson & Johnson (JNJ)
After hours:
| Previous Close | 165.54 |
| Open | 166.03 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1200 |
| Day's Range | 163.89 - 166.34 |
| 52 Week Range | 155.72 - 186.69 |
| Volume | |
| Avg. Volume | 7,077,178 |
| Market Cap | 430.37B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 29.08 |
| EPS (TTM) | 5.66 |
| Earnings Date | Apr 17, 2023 - Apr 21, 2023 |
| Forward Dividend & Yield | 4.52 (2.62%) |
| Ex-Dividend Date | Nov 21, 2022 |
| 1y Target Est | 183.80 |
- Motley Fool
3 Dow Stocks That Make for Screaming Buys in February
Out of the Dow Jones Industrial Average's 30 components, there are three amazing deals hiding in plain sight.
- Yahoo Finance
COVID is 'pretty much out of the models' for pharma companies: Wells Fargo analyst
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
- Reuters
COLUMN-3M foes act fast to capitalize on J&J’s talc bankruptcy defeat
When a U.S. appeals court ruled on Monday that Johnson & Johnson can’t use the U.S. bankruptcy system to offload vast litigation exposure from product liability claims, the people who reacted most quickly were undoubtedly J&J investors. Within hours of the 3rd U.S. Circuit Court of Appeals decision, investors drove J&J’s share price down by nearly 4% -- its biggest one-day decline in years. But another, albeit much smaller, group of people was also roiled by Monday’s ruling from the 3rd Circuit: appellate lawyers who were finishing up friend-of-the-court briefs due on Wednesday in a 7th Circuit appeal by 3M Co that presents issues similar to those in the J&J case.
